Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer? - Summary - MDSpire
Clinical Guidelines

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...

Share

Circulating tumor DNA (ctDNA) has shown potential in predicting metastatic risks in muscle-invasive bladder cancer patients, specifically regarding bladder-sparing treatments, as reported by Pooja Ghatalia, MD, at the 2026 ASCO Genitourinary Cancers Symposium. The RETAIN trials reveal that post-treatment ctDNA negativity can accurately forecast metastasis-free outcomes, although local recurrences remain challenging. Active surveillance with ctDNA assessments may guide clinical decisions for patients post-neoadjuvant therapy, while future studies aim to refine biomarkers for treatment selection.

Original Source(s)

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

  • by The ASCO Post Staff

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...